Amy Carr

461 total citations
19 papers, 269 citations indexed

About

Amy Carr is a scholar working on Infectious Diseases, Endocrinology and Molecular Medicine. According to data from OpenAlex, Amy Carr has authored 19 papers receiving a total of 269 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Infectious Diseases, 5 papers in Endocrinology and 4 papers in Molecular Medicine. Recurrent topics in Amy Carr's work include Infections and bacterial resistance (5 papers), Antibiotic Resistance in Bacteria (4 papers) and Antibiotics Pharmacokinetics and Efficacy (3 papers). Amy Carr is often cited by papers focused on Infections and bacterial resistance (5 papers), Antibiotic Resistance in Bacteria (4 papers) and Antibiotics Pharmacokinetics and Efficacy (3 papers). Amy Carr collaborates with scholars based in United States and Canada. Amy Carr's co-authors include Kathy J. Austin, Elizabeth Belden, James K. Pru, Thomas Hansen, Mitchell J. Daley, Patricia Louzon, Arnaldo Lopez‐Ruiz, Jason Sniffen, Vincent Hsu and Víctor Gallego Herrera and has published in prestigious journals such as PLoS ONE, Clinical Infectious Diseases and Endocrinology.

In The Last Decade

Amy Carr

18 papers receiving 261 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Amy Carr United States 6 94 64 63 41 40 19 269
Chia-Yin Chong Singapore 10 128 1.4× 55 0.9× 44 0.7× 8 0.2× 134 3.4× 19 327
Zhaomin Feng China 11 187 2.0× 41 0.6× 93 1.5× 23 0.6× 174 4.3× 38 429
Kuan-Ying A. Huang Taiwan 13 207 2.2× 40 0.6× 37 0.6× 32 0.8× 141 3.5× 37 401
K Fonseca Canada 10 111 1.2× 46 0.7× 58 0.9× 24 0.6× 338 8.4× 19 418
Meital Elbaz Israel 8 231 2.5× 23 0.4× 4 0.1× 42 1.0× 61 1.5× 16 330
Michael D. Nowak United States 7 244 2.6× 14 0.2× 4 0.1× 17 0.4× 133 3.3× 21 363
Nicolas Barros United States 10 95 1.0× 68 1.1× 9 0.1× 9 0.2× 93 2.3× 27 365
Flavia Hodel Switzerland 7 70 0.7× 52 0.8× 27 0.4× 27 0.7× 50 1.3× 12 293
Steven J. Sperber United States 9 53 0.6× 61 1.0× 6 0.1× 20 0.5× 118 3.0× 16 266
C. Saura France 11 83 0.9× 53 0.8× 27 0.4× 3 0.1× 181 4.5× 18 342

Countries citing papers authored by Amy Carr

Since Specialization
Citations

This map shows the geographic impact of Amy Carr's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amy Carr with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amy Carr more than expected).

Fields of papers citing papers by Amy Carr

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amy Carr. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amy Carr. The network helps show where Amy Carr may publish in the future.

Co-authorship network of co-authors of Amy Carr

This figure shows the co-authorship network connecting the top 25 collaborators of Amy Carr. A scholar is included among the top collaborators of Amy Carr based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Amy Carr. Amy Carr is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

19 of 19 papers shown
1.
Cheng, Xuanjin, Laura Williamson, Martin Krzywinski, et al.. (2024). Enhancing clinical genomic accuracy with panelGC: a novel metric and tool for quantifying and monitoring GC biases in hybridization capture panel sequencing. Briefings in Bioinformatics. 25(5). 1 indexed citations
2.
Albrecht, Benjamin, et al.. (2024). Epidemiology and treatment of invasive Bartonella spp. infections in the United States. Infection. 52(4). 1307–1314. 3 indexed citations
3.
Christians, Fred C., Kristin H. Jarman, Shivkumar Venkatasubrahmanyam, et al.. (2024). Analytical and clinical validation of direct detection of antimicrobial resistance markers by plasma microbial cell-free DNA sequencing. Journal of Clinical Microbiology. 62(10). e0042524–e0042524. 5 indexed citations
4.
5.
Louzon, Patricia, et al.. (2022). Pharmacist-Driven Methicillin-Resistant S. aureus Polymerase Chain Reaction Testing for Pneumonia. Annals of Pharmacotherapy. 57(5). 560–569. 3 indexed citations
6.
Marcella, Stephen, et al.. (2022). 666. Outcomes Using Cefiderocol for the Treatment of Acinetobacter baumannii Infections from the PROVE (Real-World Evidence) Study. Open Forum Infectious Diseases. 9(Supplement_2). 1 indexed citations
7.
Parikh, Amay, Arnaldo Lopez‐Ruiz, Joshua Goldberg, et al.. (2021). ICU outcomes and survival in patients with severe COVID-19 in the largest health care system in central Florida. PLoS ONE. 16(3). e0249038–e0249038. 83 indexed citations
8.
Ventura, D., Amy Carr, Scott Silvestry, et al.. (2021). Renin Angiotensin Aldosterone System Antagonism in 2019 Novel Coronavirus Acute Lung Injury. Open Forum Infectious Diseases. 8(10). ofab170–ofab170. 2 indexed citations
9.
Carr, Amy, et al.. (2020). 1607. Dual Therapy with Aztreonam & Ceftazidime/Avibactam Against Multi-Drug Resistant Stenotrophomonas maltophilia on Tricuspid Valve Endocarditis. Open Forum Infectious Diseases. 7(Supplement_1). S798–S798. 6 indexed citations
10.
11.
Bartelt, Luther A., Anne M. Lachiewicz, Kathleen Tompkins, et al.. (2020). Cefiderocol for the Treatment of Adult and Pediatric Patients With Cystic Fibrosis and Achromobacter xylosoxidans Infections. Clinical Infectious Diseases. 73(7). e1754–e1757. 34 indexed citations
12.
Carr, Amy, et al.. (2020). 1270. Early Real-world Evidence in the Use of Eravacycline for the Management of Draconian Infections. Open Forum Infectious Diseases. 7(Supplement_1). S651–S652. 2 indexed citations
13.
Carr, Amy, et al.. (2019). 2275. Novel Therapeutic Options for the Treatment of Multi-Drug-Resistant Achromobacter Respiratory Infections. Open Forum Infectious Diseases. 6(Supplement_2). S779–S779. 2 indexed citations
14.
Carr, Amy, et al.. (2018). Clinical Utility of Methicillin‐Resistant Staphylococcus aureus Nasal Screening for Antimicrobial Stewardship: A Review of Current Literature. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 38(12). 1216–1228. 34 indexed citations
15.
Carr, Amy, et al.. (2018). Evaluating predictors of invasive candidiasis in patients with and without candidemia on micafungin. Baylor University Medical Center Proceedings. 31(1). 30–34.
16.
Carr, Amy & Mezgebe Berhe. (2017). Risk Factors for Candidemia as Compared with Patients with Negative Blood Cultures Placed on Empiric Micafungin. Open Forum Infectious Diseases. 4(suppl_1). S79–S79. 1 indexed citations
17.
Esapa, Christopher T., Michael Cheeseman, Tertius Hough, et al.. (2009). A mouse with a Trp589Arg mutation in N-acetylgalactosaminyltransferase 3 (Galnt3) provides a model for familial tumoural calcinosis. 19. 1 indexed citations
18.
Johnson, Kevin M., B P Wordsworth, George C. Russell, et al.. (2004). ANKH mutations cause both familial and sporadic calcium pyrophosphate dihydrate chondrocalcinosis and increase ANKH transcription/2 translation.. Queensland's institutional digital repository (The University of Queensland). 50(9). 1 indexed citations
19.
Austin, Kathy J., et al.. (2003). Localization of ISG15 and Conjugated Proteins in Bovine Endometrium Using Immunohistochemistry and Electron Microscopy. Endocrinology. 145(2). 967–975. 82 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Chia-Yin Chong Breakdown of academic impact, for papers by Zhaomin Feng Breakdown of academic impact, for papers by Kuan-Ying A. Huang Breakdown of academic impact, for papers by K Fonseca Breakdown of academic impact, for papers by Meital Elbaz Breakdown of academic impact, for papers by Michael D. Nowak Breakdown of academic impact, for papers by Nicolas Barros Breakdown of academic impact, for papers by Flavia Hodel Breakdown of academic impact, for papers by Steven J. Sperber Breakdown of academic impact, for papers by C. Saura
Rankless by CCL
2026